A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-07-23
Adverse events
Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-06 (study day 3); relationship: not assessed; serious criteria: life-threatening
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-05 (study day 33); relationship: N
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-11 (study day 39); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-20 (study day 48); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 95); relationship: Y
Data queries
No data queries.